A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1646-1651

  Findlay, Brian ^a   Tonkin, K ^b   Crump, M ^c   Norris, B ^d   Trudeau, M ^e   Blackstein, M ^f   Burnell, M ^g   Skillings, J ^l   Bowman, D ^h   Walde, D ⁱ   Levine, M ^j   Pritchard, K I ^e   Palmer, M J ^k   Tu, D ^k   Shepherd, L ^k  

^a University of Toronto and Hotel Dieu Shaver Health and Rehabilitation Centre   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Princess Margaret Cancer Centre   (Canada)

^d BC Cancer Agency Fraser Valley Centre   (United Kingdom)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g SAINT JOHN REGIONAL HOSPITAL   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ Sault Area Hospitals   (Canada)

^j HENDERSON GENERAL HOSPITAL   (Canada)

^k Clinical Trials Group   (Canada)

^l NONE

more..

Author keywords

Adjuvant chemotherapy; Breast cancer; Premenopausal

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ACUTE LEUKEMIA; ADJUVANT THERAPY; ADULT; AMENORRHEA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

EID: 34848926021     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm277     Document Type: Article

References (21)

1. Fisher B, Glass A et al. L-PAM in the management of primary breast cancer. Cancer 1977; 39: 2883-2901.
2. Bonnadonna G, Brusamolino E et al. Combination chemotherapy as an adjuvant treatment in operable breast carcinoma. N Engl J Med 1976; 294: 405-410.
3. Nissen-Meyer R, Kjellgren K et al. Surgical adjuvant chemotherapy. Cancer 1978; 41: 2088-2098.
4. Bonnadonna G, Valagussa P. Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 1985; 3: 259-275.
5. Howell A, Bush H et al. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet 1984; 1: 307-311.
6. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988; 319: 1681-1692.
7. Therasse P, Mauriac L, Welnicka M et al. Neoadjuvant dose intensive chemotherapy in locally advanced breast cancer (LABC): An EORTC-NCIC-SAKK randomized Phase III study comparing FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC + G-CSF (filgrastim). ASCO Abstracts 1988; 17: 124a.
8. Levine M, Bramwell V, Pritchard K et al. A pilot study of intensive cyclophosphamide, epirubicin, and fluorouracil in patients with axillary node positive or locally advanced breast cancer. Eur J Oncol 1993; 29: 37-43.
9. Levine M, Bramwell V, Pritchard K et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol 1998; 16: 2651-2658.
10. Pritchard K, Levine MN, Bramwell VHC et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. J Clin Oncol 2005; 23: 5166-5170.
11. Misset JL, Delgado M, DeVassal F et al. Five year results of the French adjuvant trial for breast cancer comparing CMF to a combination of adriamycin, vincristine, cyclophosphamide and 5-fluorouracil. In: Salmon SE and Jones SE (eds). Adjuvant Therapy of Cancer IV. New York: Frune & Stratton 1984; 243.
12. Levine MN, Guyatt GH, Gent M et al. Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 1988; 6: 1798-1810.
13. Fleming TR. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 1982; 38: 143-151.
14. Cersosimo JF, Hong WK. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986. 425-439.
15. Shepherd L, Ottaway J, Myles J et al. Therapy-related leukemia associated with high-dose 4-epi-doxorubicin and cyclophosphamide used as adjuvant chemotherapy for breast cancer. J Clin Oncol 1994; 12: 2514-2515.
16. Palmer MJ, Pater JL, James K et al. for the National Cancer Institute of Canada Clinical Trials Group. Factors associated with fatigue in a phase one study of increasing cyclophosphamide dose. St.Gallen Breast Cancer Meeting February 1997.
17. Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15(5): 1858-1869.
18. Budman DR, Berry DA et al. for the Cancer and Leukemia Group B. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Nat Cancer Inst 1998; 90(16): 1205-1211.
19. Fisher B, Anderson S, DeCillis A. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Onool 1999; 17(11): 3374-3388.
20. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-611.
21. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1421-1439.